<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069078</url>
  </required_header>
  <id_info>
    <org_study_id>hyoscine</org_study_id>
    <nct_id>NCT04069078</nct_id>
  </id_info>
  <brief_title>Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section</brief_title>
  <official_title>Prophylactic Use of Iv Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section Under Spinal Anaesthesia. a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy of Iv hyoscine butylbromide in preventing
      Bradycardia during cesarean section under spinal anaesthesia with local anaesthetic and
      morphine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Actual">February 25, 2020</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bradycardia</measure>
    <time_frame>intraoperative</time_frame>
    <description>number of participants who will develop heart rate below 50 BPM.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Bradycardia</condition>
  <condition>Spinal Anesthetics Causing Adverse Effects in Therapeutic Use</condition>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>Hyoscine butylbromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule</intervention_name>
    <description>Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia</description>
    <arm_group_label>Hyoscine butylbromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status class I-II.

          -  Age: 18 Years to 40 Years.

          -  Women scheduled for elective Cesarean section under spinal anesthesia.

          -  indications for CS other than fetal or maternal pathology.

        Exclusion Criteria:

          -  Height &lt; 150 or &gt; 180 cm

          -  Body mass index (BMI) &gt;35 kg/m2

          -  Contraindication for central neuraxial block

          -  Refusal to undergo regional anesthesia

          -  Known allergy to any of the study drugs,

          -  Infection at the site of injection,

          -  Coagulopathy,

          -  Indication to general anesthesia

          -  Baseline bradycardia (heart rate &lt; 60/min), or any cardiovascular disease

          -  Patients taking Î²-adrenergic blockers or any drugs that may alter normal response to
             study drugs.

          -  Arrhythmia such as atrial fibrillation, supraventricular tachycardia, heart block
             greater than first degree, left bundle branch block,

          -  Hypertension (systolic blood pressure more than 140 mm Hg or diastolic blood pressure
             more than 90 mm Hg), unstable angina or cardiomyopathy,

          -  Associated medical problem with pregnancy (as hypertension, diabetes mellitus, hepatic
             impairment or renal impairment)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut University hospital</name>
      <address>
        <city>Assiut</city>
        <state>Asyut Governorate</state>
        <zip>11111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mostafa Samy Abbas</investigator_full_name>
    <investigator_title>associate professor of anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

